These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Health-related quality of life in HIV patients switching to twice-daily indinavir/ritonavir regimen or continuing with three-times-daily indinavir-based therapy. Badía X; Podzamczer D; Moral I; Roset M; Arnaiz JA; Loncà M; Casiró A; Rosón B; Gatell JM; Antivir Ther; 2004 Dec; 9(6):979-85. PubMed ID: 15651756 [TBL] [Abstract][Full Text] [Related]
26. Dual PI therapy emerges as most viable combination. AIDS Alert; 1997 Dec; 12(12):133-5. PubMed ID: 11364830 [TBL] [Abstract][Full Text] [Related]
27. Adherence to antiretroviral therapy and outcomes in HIV-infected patients enrolled in an induction/maintenance randomized trial. Flandre P; Peytavin G; Meiffredy V; Saidi Y; Descamps D; Delagnes M; Brun-Vézinet F; Raffi F; Antivir Ther; 2002 Jun; 7(2):113-21. PubMed ID: 12212923 [TBL] [Abstract][Full Text] [Related]
28. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors. Chetchotisakd P; Anunnatsiri S; Mootsikapun P; Kiertiburanakul S; Anekthananon T; Bowonwatanuwong C; Kowadisaiburana B; Supparatpinyo K; Ruxrungtham K; HIV Med; 2007 Nov; 8(8):529-35. PubMed ID: 17944686 [TBL] [Abstract][Full Text] [Related]
29. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study. Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096 [TBL] [Abstract][Full Text] [Related]
30. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy. Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927 [TBL] [Abstract][Full Text] [Related]
31. Regimen-dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor-based highly active antiretroviral therapy. Moore DM; Hogg RS; Yip B; Wood E; Harris M; Montaner JS HIV Med; 2006 Jul; 7(5):311-6. PubMed ID: 16945076 [TBL] [Abstract][Full Text] [Related]
32. After the drugs: what's next? Schouten JT Res Initiat Treat Action; 1998 Dec; 4(7):9-10. PubMed ID: 11366085 [TBL] [Abstract][Full Text] [Related]
33. Update from the 5th Conference on Retroviruses and Opportunistic Infections. Vazquez E Posit Aware; 1998; 9(3):21-3. PubMed ID: 11365483 [TBL] [Abstract][Full Text] [Related]
34. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults. Ribera E; Lopez RM; Diaz M; Pou L; Ruiz L; Falcó V; Crespo M; Azuaje C; Ruiz I; Ocaña I; Clotet B; Pahissa A Antimicrob Agents Chemother; 2004 Nov; 48(11):4256-62. PubMed ID: 15504850 [TBL] [Abstract][Full Text] [Related]
35. A once-daily HAART regimen containing indinavir + ritonavir plus one or two nucleoside reverse transcriptase inhibitors (PIPO study). Burger DM; Aarnoutse RE; Dieleman JP; Gyssens IC; Nouwen J; de Marie S; Koopmans PP; Stek M; van der Ende ME Antivir Ther; 2003 Oct; 8(5):455-61. PubMed ID: 14640393 [TBL] [Abstract][Full Text] [Related]